Results 21 to 30 of about 137,002 (346)
Metabolites, 2021 To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs).
A. Mantovani +5 more
semanticscholar +1 more source
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
JAMA Health Forum, 2021 Key Points Question Are there inequities in glucagon-like peptide-1 receptor agonist (GLP-1 RA) use based on race, ethnicity, sex, and socioeconomic status among patients with diabetes in the US?
L. Eberly +12 more
semanticscholar +1 more source
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. [PDF]
, 2015 © 2015 The Authors.Objective: Although Glucagon-like peptide 1 is a key regulator of energy metabolism and food intake, the precise location of GLP-1 receptors and the physiological relevance of certain populations is debatable.
Cork, SC +5 more
core +2 more sources
The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma [PDF]
Exploration of Asthma & AllergyGlucagon-like peptide-1 (GLP-1) is a hormone that regulates blood glucose levels and is produced by the enteroendocrine glands in the large and small intestines in response to the consumption of foods that contain carbohydrates, fats, and proteins.
Courtney Lehman, Ray Stokes Peebles Jr
doaj +1 more source
Nature Communications, 2020 Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast +25 more
doaj +1 more source
Reviews in Endocrine & Metabolic Disorders, 2022 Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist).
Manojkumar Mahapatra +2 more
semanticscholar +1 more source
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]
, 2014 Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core +1 more source
Journal of Personalized Medicine, 2022 The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex.
Elpiniki Rentzeperi +4 more
semanticscholar +1 more source
In Vivo Imaging of Transplanted Islets with ^(64)Cu-DO3A-VS-Cys^(40)-Exendin-4 by Targeting GLP-1 Receptor [PDF]
, 2011 Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in pancreatic islets, especially on β-cells. Therefore, a properly labeled ligand that binds to GLP-1R could be used for in vivo pancreatic islet imaging.
Bading, James R. +11 more
core +2 more sources